Other papers, indeed, have demonstrated the efficacy of ATRA in preventing Nrf2 binding on its target genes [58] and recently the efficacy of ATRA in reducing HO-1 transcription and in decreasing GSH content has been clearly shown in leukemia cells [68]. The gene discussed is NFE2L2; the disease is leukemia.